Opaleye Management Inc. bought $124k of GRCE
owner at Grace Therapeutics, Inc.. 60,490 shares at an average of $2.05, traded Oct 1, 2026, filed Oct 5, 2026.
Score components
- +12Role10% owner
- +10Trade size$124k at market
- 0Relative to holdingsHoldings up 2.2%
- +18Price context0% above the 52-week low; 60% below the 52-week high
- 0ClusterNo other insider buying within 14 days
- +5Repeat buying5 buys in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
- -5Outside holderA 10% owner who is not an officer or director
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001493152-26-045809, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 1, 2026 | POpen-market purchase Common Stock, par value $0.0001 per shareindirect: By Opaleye, L.P. | +38,796 | $2.04 | $79k | 2,836,963 | 7 d ago |
| Oct 2, 2026 | POpen-market purchase Common Stock, par value $0.0001 per shareindirect: By Opaleye, L.P. | +20,000 | $2.07 | $41k | 2,856,963 | 7 d ago |
| Oct 5, 2026 | POpen-market purchase Common Stock, par value $0.0001 per shareindirect: By Opaleye, L.P. | +1,694 | $2.06 | $3,490 | 2,858,657 | 7 d ago |
Related signals
Other insiders at Grace Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 25Weak | GRCEbuy Grace Therapeutics, Inc. | Opaleye Management Inc. owner | $16k 7,849 shares | +0% | |
| 38Weak | Grace Therapeutics, Inc. | Opaleye Management Inc. owner | $32k 15,089 shares | +1% | |
| 38Weak | Grace Therapeutics, Inc. | Opaleye Management Inc. owner | $32k 15,089 shares | +1% | |
| 73Notable | Grace Therapeutics, Inc. | Prashant Kohli Chief Executive Officer | $214k 100,000 shares | +468% | |
| 33Weak | Grace Therapeutics, Inc. | Opaleye Management Inc. owner | $32k 15,229 shares | +1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.